Call: +1 (800) 752-8538

2015-03-02: Unique Filtration-Based Technology

C-PET™ Therapy is Flexible – Any Size Dog Can be Treated!

The unique filtration-based technology in the C-PET™ provides veterinarians with unprecedented flexibility in preparing a platelet therapy. Whether treating a 15 pound Terrier, a 25 pound Beagle, or a 150 pound Mastiff, C-PET™ lets you choose the blood draw volume that is right for your patient.

C-PET™ is the most flexible solution. Unlike most centrifugation based procedures used to prepare platelet therapies, C-PET™ volumes can be adjusted to accommodate the size of the animal by varying the volume of blood drawn, and the volume of solution used to recover the platelet therapy from the filter. Use the Treatment Volume Matrix below to choose the platelet fold increase you desire for treatment of any size dog.

The platelet fold increase values above represent estimates based on multiple runs from multiple donors. As with all platelet concentration devices, the actual fold increase in platelets for individual processing events is highly donor dependent and can vary widely.

Note that data provided in the C-PET™ Field Trial Report (March 2012, GN12.7960), and the C-PET™ Clinical Report presented at the 2012 Veterinary Orthopedic Society (VOS) conference1 were produced using the standard instructions for use, denoted by an asterisk (*) above.

2015-02-12: Canine Platelet Therapy a Winner

Help Your Client's Dogs Feel Young Again!

Canine Platelet Enhanced Therapy (C-PET™) from Pall Corporation and distributed by Canine Partners America, LLC is light, portable, and easy to use. A perfect addition for general practitioners looking for non-invasive, low morbidity options to treat of tendon and ligament damage, and osteoarthritis. It is a non-surgical, non-pharmaceutical outpatient procedure requiring no centrifuge or additional equipment that can be done in the office, in the field, or even in a client’s home. It’s just 15 minutes from blood draw to delivery; a single treatment takes 30 minutes. The gentle gravity filtration is easy on platelets, creating a high quality platelet therapy rich in growth factors. Autologous preparation reduces the risk of immune mediated reactions.

2014-06-15: Dr. Schaffer & Moira McCracken visit new C-PET Clinics

C-PET On the Rise in Small Animal Clinics on the East Coast.

Dr. Jeff Schaffer of Pall Corporation and Moira McCracken visited Countryside Veterinary Services in Louisville, TN where Dr. Schaffer assisted Dr. Monica Webb of Countryside with her first patients using C-PET. History was made when the C-PET product was used on its first Chihuahua, Chica, with great success!

The evening before was spent presenting C-PET and Pall’s scientific findings to the board of 12 veterinarians of An-Emerge, in North Georgia.

Dr. Schaffer also visited Dr. John McGruder of Crestview Animal Hospital in Cumming, GA, educating the Crestview staff on the C-PET procedure for their use.

 

"CHICA - ELBOW"

"LARGE DOG - KNEE"

Check out our photos on FACEBOOK!

About Pall Corporation
Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide.

2014-05-16: C-PET lab - Murrayville Veterinary Clinic

Murrayville Vet Clinic & Gwinnett Animal Hospital, support (C-PET™) for Treatment of Osteoarthritis (OA) in Dogs by participating in Practical Labs

Pictoral View of Procedures

 

2013-12-17: Clinical Research Proves Efficacy of of C-PET

Clinical Research Proves Efficacy of Canine Platelet Enhancement Therapy (C-PET™) for Treatment of Osteoarthritis (OA) in Dogs

Results Published in Recent Issue of the Journal of the American Veterinary Medical Association

PORT WASHINGTON, N.Y., December 17, 2013 - A randomized, controlled study organized by The Ohio State University and Western University Health Sciences shows efficacy of autologous platelet therapy for treatment of osteoarthritis (OA) in dogs using Pall’s Canine Platelet Enhancement Therapy (C-PET™) kit. The findings of the study, which were published in the November 1, 2013 issue of the Journal of the American Veterinary Medical Association (JAVMA), offer clinical relevance proving that a single intra-articular injection of autologous platelets can significantly improve dogs with OA.

The study evaluated 20 client-owned dogs diagnosed with OA in a single joint. The dogs were randomly assigned to either a treatment group or a control group. They weighed from 40 to 140 pounds, included a wide array of breeds, and ranged in age from 1.5 to 8 years. Lameness of each dog was assessed by their owners using the Hudson Visual Analog Scale (HVAS). Pain was evaluated using the University of Pennsylvania’s Canine Brief Pain Inventory (CBPI).The objective measurement of function and weight bearing was determined by the “gold standard” force plate measurement of peak vertical force (PVF)1.

The results showed dogs that received C-PET™ platelet injections significantly improved lameness scores, pain scores and PVF after 12 weeks, compared with pre-treatment values. In contrast, control dogs’ lameness scores, pain scores and PVF at week 12 were not significantly different from pre-treatment values.

C-PET™ provides a minimally invasive treatment for OA in dogs. It is safe, effective and convenient. The entire procedure requires about 30 minutes, as documented in the study. It is important to note that not all platelet-rich plasma (PRP) preparation techniques are the same. Therefore, the success or failure of a specific PRP product is not necessarily predictive of all PRP preparations. Well-designed, prospective, randomized, blinded (Level 1) clinical studies are needed to carefully and comprehensively investigate the role of the various PRP preparations. Pall’s C-PET™ is the first proven technique with objective clinical data published in the JAVMA study.

About Pall Corporation
Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide.

2013-11-20

On-Demand C-PET Webinar (earn CEU Credit)!

Discover a New Filter-based Preparation of Platelet Therapy for Canine Osteoarthritis Treatment

In this webinar you will explore cell therapy and demystify the theory supporting intra-articular injection of platelet therapy. You will review the results of clinical evaluations, as well as provide details of the method of treatment, and describe tools that can be used to easily assess clinical value. Learn more and register to view

design by GrafX by Laurie